Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2017 | 1 |
2018 | 1 |
2020 | 2 |
2021 | 2 |
2022 | 1 |
2024 | 0 |
Search Results
6 results
Results by year
Filters applied: . Clear all
Page 1
Panobinostat enhances olaparib efficacy by modifying expression of homologous recombination repair and immune transcripts in ovarian cancer.
Neoplasia. 2022 Feb;24(2):63-75. doi: 10.1016/j.neo.2021.12.002. Epub 2021 Dec 20.
Neoplasia. 2022.
PMID: 34933276
Free PMC article.
Entinostat, a selective HDAC1/2 inhibitor, potentiates the effects of olaparib in homologous recombination proficient ovarian cancer.
Gupta VG, Hirst J, Petersen S, Roby KF, Kusch M, Zhou H, Clive ML, Jewell A, Pathak HB, Godwin AK, Wilson AJ, Crispens MA, Cybulla E, Vindigni A, Fuh KC, Khabele D.
Gupta VG, et al.
Gynecol Oncol. 2021 Jul;162(1):163-172. doi: 10.1016/j.ygyno.2021.04.015. Epub 2021 Apr 16.
Gynecol Oncol. 2021.
PMID: 33867143
Free PMC article.
Item in Clipboard
Ascites-induced compression alters the peritoneal microenvironment and promotes metastatic success in ovarian cancer.
Asem M, Young A, Oyama C, ClaureDeLaZerda A, Liu Y, Ravosa MJ, Gupta V, Jewell A, Khabele D, Stack MS.
Asem M, et al.
Sci Rep. 2020 Jul 17;10(1):11913. doi: 10.1038/s41598-020-68639-2.
Sci Rep. 2020.
PMID: 32681052
Free PMC article.
Item in Clipboard
CCNE1 and BRD4 co-amplification in high-grade serous ovarian cancer is associated with poor clinical outcomes.
Petersen S, Wilson AJ, Hirst J, Roby KF, Fadare O, Crispens MA, Beeghly-Fadiel A, Khabele D.
Petersen S, et al.
Gynecol Oncol. 2020 May;157(2):405-410. doi: 10.1016/j.ygyno.2020.01.038. Epub 2020 Feb 7.
Gynecol Oncol. 2020.
PMID: 32044108
Free PMC article.
Item in Clipboard
The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer.
Wilson AJ, Stubbs M, Liu P, Ruggeri B, Khabele D.
Wilson AJ, et al.
Gynecol Oncol. 2018 Jun;149(3):575-584. doi: 10.1016/j.ygyno.2018.03.049. Epub 2018 Mar 20.
Gynecol Oncol. 2018.
PMID: 29567272
Free PMC article.
Item in Clipboard
BET Bromodomain Inhibition Synergizes with PARP Inhibitor in Epithelial Ovarian Cancer.
Karakashev S, Zhu H, Yokoyama Y, Zhao B, Fatkhutdinov N, Kossenkov AV, Wilson AJ, Simpkins F, Speicher D, Khabele D, Bitler BG, Zhang R.
Karakashev S, et al.
Cell Rep. 2017 Dec 19;21(12):3398-3405. doi: 10.1016/j.celrep.2017.11.095.
Cell Rep. 2017.
PMID: 29262321
Free PMC article.
Item in Clipboard
Cite
Cite